Article
RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer.
Cancer science - 1 Jul 2014
Kaneto Naoki, Yokoyama Satoru, Hayakawa Yoshihiro, Kato Shinichiro, Sakurai Hiroaki, Saiki Ikuo
Abstract excerpt
Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKI), including gefitinib, provide a significant clinical benefit in non-small-cell lung cancer (NSCLC) patients, the acquisition of drug resistance has been known to limit the efficacy of EGFR-TKI therapy. In this study, we demonstrated the involvement of EGF-EGFR signaling in NSCLC cell migration and the requirement of RAC1 in...
Topics
- Aminoquinolines
- Animals
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- Cell Movement
- Drug Resistance, Neoplasm
- ErbB Receptors
- Female
- Gefitinib
- Gene Silencing